MedPath

Cefazolin

Cefazolin for Injection, USP

Approved
Approval ID

e8bd9e95-8af5-416b-b58c-e1dbe3d052ac

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 18, 2023

Manufacturers
FDA

Qilu Pharmaceutical Co., Ltd.

DUNS: 653878256

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cefazolin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code67184-0560
Application NumberANDA203661
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cefazolin
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateDecember 18, 2023
FDA Product Classification

INGREDIENTS (1)

CEFAZOLIN SODIUMActive
Quantity: 2 g in 1 1
Code: P380M0454Z
Classification: ACTIM

Cefazolin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code67184-1001
Application NumberANDA203661
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cefazolin
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateDecember 18, 2023
FDA Product Classification

INGREDIENTS (1)

CEFAZOLIN SODIUMActive
Quantity: 1 g in 1 1
Code: P380M0454Z
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cefazolin - FDA Drug Approval Details